Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFH772 in rosacea
NCT01449591Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BFH772 in rosacea, sponsored by Novartis. Primary endpoint: Investigator's assessment of facial erythema score at 12 weeks. Started Sep 2011; status: completed.
02
Drugs
BFH772
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT01449591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01449591.